Facilitators and Barriers to Pre-Exposure Prophylaxis Willingness Among Young Men Who Have Sex with Men Who Use Geosocial Networking Applications in California. by Holloway, Ian W et al.
UCLA
UCLA Previously Published Works
Title
Facilitators and Barriers to Pre-Exposure Prophylaxis Willingness Among Young Men Who 
Have Sex with Men Who Use Geosocial Networking Applications in California.
Permalink
https://escholarship.org/uc/item/5d1875w0
Journal
AIDS patient care and STDs, 31(12)
ISSN
1087-2914
Authors
Holloway, Ian W
Tan, Diane
Gildner, Jennifer L
et al.
Publication Date
2017-12-01
DOI
10.1089/apc.2017.0082
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
BEHAVIORAL AND PSYCHOSOCIAL RESEARCH
Facilitators and Barriers to Pre-Exposure Prophylaxis
Willingness Among Young Men Who Have Sex with Men
Who Use Geosocial Networking Applications in California
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Craig Pulsipher, MSW, MPP,2 Jorge A. Montoya, PhD,3 Aaron Plant, MPH,3 and Arleen Leibowitz, PhD1
Abstract
While correlates of pre-exposure prophylaxis (PrEP) uptake have been explored among older men who have sex
with men (MSM), less is known about the facilitators and barriers that encourage uptake among younger MSM
(YMSM). This study explores the association between willingness to take PrEP and demographic character-
istics, sexual risk, and substance use, and attitudinal factors among YMSM in California who use geosocial
networking applications (GSN apps). Based on survey data from YMSM recruited through GSN apps (n = 687),
PrEP willingness was positively associated with Hispanic ethnicity [adjusted odds ratio (aOR): 1.73; confidence
interval (CI): 1.01–2.98; p= 0.046], concerns about drug effects (aOR: 0.46; CI: 0.33–0.65; p < 0.001), medical
mistrust (aOR: 0.71; CI: 0.53–0.96; p < 0.001), and concerns about adherence (aOR: 0.65; CI: 0.49–0.89;
p = 0.005). PrEP willingness was positively associated with medium (aOR: 1.87; CI: 1.14–3.07; p = 0.014) and
high concern (aOR: 1.84; CI: 1.13–3.01; p< 0.001) about contracting HIV and perceived benefits of taking PrEP
(aOR: 2.59; CI: 1.78–3.78; p< 0.001). In addition to emphasizing the benefits of using PrEP, campaigns that
address concerns regarding adherence and side effects may increase interest in and demand for PrEP among
YMSM. More opportunities are needed to educate YMSM about PrEP, including addressing their concerns
about this new prevention strategy. Providers should speak openly and honestly to YMSM considering PrEP
about what to do if side effects occur and how to handle missed doses. Outreach using GSN apps for PrEP
education and screening may be an effective way to reach YMSM.
Keywords: pre-exposure prophylaxis (PrEP), young men who have sex with men (YMSM), social networking,
medication adherence, medical mistrust
Introduction
The HIV epidemic in the US continues to dispropor-tionately impact vulnerable and marginalized commu-
nities. While incidence remains high among gay, bisexual,
and other men who have sex with men (MSM), the burden is
shifting from white to black and Latino MSM.1–4 According
to the CDC,5 nearly half of black MSM and one quarter of
Latino MSM will be diagnosed with HIV in their lifetimes
(compared to one in 11 white MSM) if current infection rates
continue, with a majority of those infections attributable to
same-sex sexual contact.3 The burden is also shifting from
older to younger MSM (YMSM), with as many as two-thirds
of newHIV infections among youth also attributable to same-
sex sexual contact.6 YMSM of color have been particularly
affected, with HIV prevalence among these men rising ac-
cording to recent estimates.7,8 The HIV epidemic in Cali-
fornia largely reflects these trends.9,10
Some prevention efforts specifically target YMSM,11 and
more are warranted; however, broader epidemiological ana-
lyses suggest that the effect of behaviorally focused HIV
prevention efforts on new infections may have plateaued.12
Thus, in recent years, attention has turned to and enthusiasm
has grown for biomedical approaches to HIV prevention. The
‘‘test and treat’’ model, for example, involves routinizing
testing for at-risk populations, linking to care those who test
1University of California, Los Angeles, Los Angeles, California.
2AIDS Project, Los Angeles, California.
3Sentient Research, Los Angeles, California.
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positive, and ensuring care for those already positive to de-
crease community viral load.13–15 Pre-exposure prophylaxis
(PrEP), the use of antiretroviral medications by HIV-negative
individuals to prevent infection, is a newly available and
promising biomedical tool. Clinical trials estimate that, when
taken consistently, PrEP can reduce HIV infection risk by as
much as 99%.16–18 In the years following its introduction,
studies demonstrated that efficacy remains relatively high even
with imperfect use (e.g., 76% reduction with five missed doses
per week; 96% with three).16 Also, concerns about PrEP use
causing mutations in the HIV virus have largely been allayed.
Studies have shown that drug resistance is rare enough that the
potential benefit of avoiding HIV infection far outweighs the
risk of seroconversion by mutated virus while on PrEP.19–21
Understandably then, PrEP has been integrated into many
new prevention efforts across the United States, including
California’s ‘‘Laying a Foundation for Getting to Zero’’
initiative.22 Previous research, however, has found that de-
spite increasing awareness of and interest in PrEP, uptake
remains low, often as little as 1–5% of MSM report having
ever taken it.23–29 While some evidence suggests this is likely
to increase over time,30,31 remaining barriers threaten to
stymie a broader uptake. Studies show that access to PrEP
(i.e., its cost and the cost of health insurance coverage more
broadly), the health effects of PrEP (i.e., its side effects and
consequences of long-term use), and behavior change related
to PrEP (i.e., medication adherence and fears that a decreased
perception of risk will lead to increased risk behavior, or what
is broadly referred to as ‘‘risk compensation’’) remain sig-
nificant barriers to uptake among MSM.32–38
Stigma associated with taking PrEP is another barrier, with
some MSM reporting being afraid of or having experienced
moral judgment and shaming from their peers as well as their
health providers.39–42 Concerns about stigma are not un-
founded: one study showed that members of the general public
expressed lower support for funding policies and programs that
would facilitate access to PrEP for gay men, with gay black
men receiving the least expressed support relative to expressed
support for the general population.43 While some research has
shown YMSM face similar stigma,23,44–46 much less is known
about the barriers and facilitators to PrEP willingness and
uptake for this population.
Many studies of PrEP involving MSM have emerged from
preliminary investigations into its feasibility and acceptability,
or clinical determinations of its efficacy. Since its approval in
2012, there have been several studies of MSM’s attitudes to-
ward PrEP and recent studies have begun to focus on correlates
of PrEP uptake, given limitations of studying PrEPwillingness
and intentions to use PrEP.47 However, many of these samples
of MSM trend toward older or whiter MSM, with some re-
porting higher levels of education and income relative to
YMSM.23,48–51 As such, it remains unclear whether these data
reflect the attitudes, behaviors, and experiences of YMSM,
especially YMSM of color, or whether men in these samples
have similar risk behavior profiles to YMSM.
Previous studies of PrEP that do involve YMSM have
shown low awareness23,44 and moderate-to-high willing-
ness,45,52 with concerns regarding accessing PrEP a com-
monly reported barrier.23,44,46 While these studies provide
valuable insight into MSM’s attitudes toward and use of
PrEP, important questions remain unanswered for YMSM.
Data on a full range of barriers and facilitators, as well as their
saliency, for PrEP willingness and uptake among YMSM are
lacking, as are data on the associations between sexual risk
and substance use on YMSM’s attitudes toward PrEP. With
many YMSM seeking sexual partners through online- and
smartphone-based social networking applications (hereafter
referred to as GSN apps), it is imperative that this potentially
high-risk population be included in future investigations.53–57
This study explores the association between willingness to
take PrEP and demographic characteristics, sexual risk, and
substance use, and attitudinal factors among YMSM in Ca-
lifornia who use GSN apps. Its aim is to better understand the
barriers and facilitators for PrEP willingness and uptake
among a diverse sample of YMSM at risk for HIV infection,
to inform multi-level intervention efforts that may improve
PrEP uptake in this population.
Methods
Participants and procedures
This analysis utilizes anonymous survey data collected
online from July 9 to August 20, 2015. Potential participants
were recruited through several popular GSN apps for YMSM,
where they received push notifications advertising the sur-
vey. Those interested were first asked if they were willing to
participate, and then were given an online screener to assess
their eligibility. Participants had to be: 18–29, assigned male
sex at birth, sexually active with other men in the last 5 years,
HIV negative, and a California resident. Eligible participants
clicked through to an online survey that took *20min to
complete. Upon its completion, participants gave their email
address for a $25 electronic gift card incentive. All study
procedures were approved by the North Campus Institutional
Review Board at the University of California, Los Angeles.
Measures
PrEP willingness. Participants were asked if they had
heard about PrEP and, if so, where they had heard about it
(e.g., friend, family member, doctor, sex partner, social media,
online/internet, magazine/newspaper, television/radio, HIV/
AIDS organization, LGB/T organization, don’t know/unsure,
or other). They were also asked about additional sources of
PrEP awareness such as knowing someone personally who had
taken it. Finally, they were asked if they felt they had adequate
information to make a decision about taking PrEP. Next,
participants were given a brief description of PrEP that in-
cluded facts about themedication, such as its purpose, efficacy,
dosage, side effects, and required medical follow-ups. Parti-
cipants were then asked to rate (on a 6-point scale ranging from
‘‘extremely unlikely’’ to ‘‘extremely likely’’) how likely they
would be to take PrEP. Specifically, participants were asked,
‘‘Given this information, how likelywould you be to take PrEP
if it was available to you?’’ Those indicating ‘‘very likely’’ or
‘‘extremely likely’’ were considered willing to take PrEP; all
others were considered unwilling or uninterested.
Demographics. A comprehensive battery of demographic
questions was asked of participants, including race/ethnicity
(white, black, Latino, Asian, other/mixed), age (dichotomized
to mirror CDC age categorization: 18–24 and 25–29), gender
identity (man or other), sexual orientation (gay, bisexual, or
other), sexual behavior in the past 5 years (men only, men and
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women), employment (full time, part time, student, and other),
education (less than high school, high school, and some col-
lege and above), income (<$9999, $10,000–$29,999, and
>$30,000), insurance status (insured and not insured), home-
less in the past year (yes or no), and US citizenship (yes or no).
HIV risk behaviors. Questions regarding sexual risk per-
tained to behaviors in the past 6 months and included number
of male sexual partners (count), instances of receptive and/or
insertive condomless anal sex (CAS) (count), number of
HIV-positive male partners, and exchanging sex for money
(yes or no). Other risk factors measured were sexually
transmitted infection (STI) diagnoses in the past year (yes or
no), illicit substance use in the last 6 months (i.e., metham-
phetamine/crystal, heroin, cocaine/crack, ecstasy/MDMA/
Molly, Ketamine/Special K, and GHB), last HIV and STI
test (never tested, <6months, 6–12 months, and >12 months),
and self-rated risk and concern for getting HIV (1= low,
2 =moderate, and 3= high). Using six of these risk measures
(age, number of partners, receptive CAS, HIV-positive part-
ners, insertive CAS with an HIV-positive man, and meth-
amphetamine use), we assigned a risk score to participants
based on the CDC’s recommendations.58 Those with scores
‡10 were considered high risk and recommended for PrEP
screening. A score ‡10 could be achieved in two ways: cu-
mulatively, as a sum total of points scored across various
measures, or at once, if the participant reported any receptive
CAS in the past 6 months.
PrEP attitudes. Participants were asked to rate their agree-
ment (on a 4-point scale, ranging from ‘‘strongly disagree’’ to
‘‘strongly agree’’) with 33 statements about PrEP to assess
their attitudes toward the prevention strategy (Table 3).
These statements were derived from previous research on
barriers and facilitators to PrEP use among MSM.23,59
Data analysis
We used principal component analysis as a data reduction
strategy for the 33 PrEP attitude statements; our goal was to
reduce the large number of single items into parsimonious
factors.60 Items that did not load onto any factors at a cutoff of
0.5 were excluded. We used a scree plot to determine the
appropriate number of factors and assigned items to factors
based on loadings >0.5. Each factor was scored by averaging
the items that loaded onto that particular factor. All nega-
tively worded items were reverse coded so that higher scores
reflected greater willingness to take PrEP.
Bivariate chi-square tests comparing characteristics (de-
mographics and risk behaviors) of those willing to take PrEP
versus those unwilling/uninterested in taking PrEP were
performed to determine variables of interest for inclusion in a
multivariable model. To compare attitudinal differences be-
tween willing and unwilling/uninterested participants, we
used the Mann-Whitney test due to non-normality of the
factor scales. To adjust for multiple comparisons on the same
sample, we used the Benjamini and Hochberg procedure to
control the false discovery rate at the 0.05 alpha level.61
Variables significant at the bivariate level and conceptually
relevant covariates were included in a multivariable logistic
regression model predicting willingness to take PrEP.
Results
Participant characteristics
Of 3868 participants who expressed interest in the survey,
3842 were consented and screened for eligibility. Only 1777
met inclusion criteria and 762 went on to complete the entire
survey. After removing one duplicate survey (determined by
IP address), 761 participants remained, of whom 687 had
never taken PrEP and were included in our sample. Our
overall response rate was higher than previous studies re-
cruiting YMSM through GSN apps in California, which
range from 9% to 13%.54,62,63 About 43% of participants
were from the greater Los Angeles area, 25% were from the
Bay Area, and the remaining 32% were from other regions in
California. Mean age was 23 years. In terms of race/ethnicity,
33%were Latino, 25%were black, 21%were white, and 21%
were other/mixed. Most identified as male (97%), had sex
with men exclusively (82%), and identified as gay (80%).
Smaller percentages identified as bisexual (17%) or another
sexual orientation (3%). Forty percent worked full time,
while 23% worked part time and 25% were students. Most
completed high school (93%) and over half indicated an
annual income <$30,000 (63%). Three-quarters indicated
being insured (74%) and nearly all were US citizens (90%).
Sources of knowledge, PrEP willingness,
and demographic characteristics
Nearly three-quarters of the sample (74%) had heard about
PrEP previously, citing social media (57%), the internet
(51%), and friends (47%) as sources. Over half (55%) were
willing to take PrEP. Significantly more YMSMwho reported
adequate information to make a decision about whether to take
PrEP were willing to use it compared to those who were un-
willing/uninterested (33% vs. 20%, p< 0.001). There were no
statistically significant associations between prior knowledge
of PrEP, or source of PrEP information, and willingness. Race/
ethnicity (v2= 10.1; p= 0.04), age (v2= 10.1; p= 0.002), em-
ployment status (v2= 10.6; p= 0.01), education level (v2= 9.8;
0.007), and income (v2= 9.1; p= 0.01) were significantly as-
sociated with willingness to take PrEP. See Table 1 for a list of
all demographic comparisons.
Sexual risk behavior and substance use
Reported sexual risk was high: over 68% of men in the
sample scored 10 or higher on the CDC’s HIV risk index. The
average number of sexual partners in the last 6 months was
seven (standard deviation= 20.7); the median number of sex-
ual partners in the last 6 months was four (interquartile range,
2–8). Over half reported receptive CAS with a partner of
any serostatus (52%) and over one-fifth reported insertive
CAS with an HIV-positive partner (22%). Substance use was
common: over three-quarters used alcohol (77%); nearly half
used marijuana (43%); over one-fifth used poppers (22%); and
nearly one-fifth used an illicit substance (17%) in the past 6
months. Willingness to take PrEP was significantly associated
with time since last HIV test (v2= 11.9; p= 0.008), level of
concern about becoming infected with HIV (v2= 30.0;
p< 0.001), recent receptive CAS (v2= 14.6; p< 0.001), use of
illicit drugs in the past 6 months (v2= 4.9; p= 0.026), and HIV
risk index score (v2= 8.3; p= 0.004). See Table 2 for a full
listing of sexual risk and substance use behavior comparisons.
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Principal component analysis
and attitudes toward PrEP
Principal component analysis yielded 8 unique factors to
assess attitudes about PrEP. Six of the 33 statements regarding
PrEPwere excluded from the final set because they did not load
onto any of the factors, did not load on any factor above 0.5, or
were not conceptually aligned with other items within a single
factor. Two items: ‘‘I would take PrEP if there weren’t any side
effects’’ and ‘‘I don’t trust drug companies’’ loaded onto two
factors; so they were assigned to the factor with the higher
loading. Based on the results of the factor analysis, we identified
the following categories for measuring attitudes and concerns
about PrEP: access/affordability, stigma and disclosure, drug
effects, perceived benefits, risk compensation, lack of perceived
need, medical mistrust, and adherence. See Table 3 for a list of
items within each factor and accompanying factor loadings.
With the exception of access/affordability, all attitudinal
measures were significantly associated with willingness to
take PrEP ( p< 0.001 in all cases). YMSM who were un-
willing to take or uninterested in taking PrEP had more
concerns about stigma, drug effects, risk compensation, ne-
cessity, medical mistrust, and adherence. However, partici-
pants who indicated they would be willing to take PrEP had
higher perceived benefits of the prevention strategy. See
Table 4 for a summary of attitudinal analyses.
Multivariable regression
Hispanic/LatinoYMSMweremore likely thanwhite YMSM
to be willing to take PrEP [odds ratio (OR): 1.73; confidence
interval (CI): 1.01–2.98; p= 0.046]. Compared to YMSM re-
porting low concern for getting HIV, those with medium (OR:
1.87; CI: 1.14–3.07; p= 0.014) and high concern (OR: 1.84; CI:
1.13–3.01; p=0.015) were nearly twice as likely to be willing to
take PrEP. Greater concerns about PrEP drug effects were as-
sociated with decreased odds of being willing to take it (OR:
0.46; CI: 0.33–0.65; p<0.001). Increased medical mistrust was
associated with decreased willingness to take PrEP (OR: 0.71;
CI: 0.53–0.96; p=0.026). Finally, greater concerns regarding
Table 1. Demographic Characteristics Among Younger Men Who Have Sex with Men
in California By Willingness (n = 687)
Characteristic Total, n (%) Willing, n (%) Unwilling or uninterested, n (%) v2 (p value)
687 (100.0) 380 (55.3) 307 (44.7)
Race/ethnicity 10.1 (0.04)
White 142 (20.7) 70 (18.4) 72 (23.5)
Black 174 (25.3) 90 (23.7) 84 (27.4)
Latino 227 (33.0) 144 (37.9) 83 (27.0)
Asian 44 (6.4) 21 (5.5) 23 (7.5)
Other/mixed 100 (14.6) 55 (14.5) 45 (14.7)
Mean age (SD) 23 (3.2) 23 (3.2) 24 (3.1)
Age category 10.1 (0.002)
18–24 434 (63.2) 260 (68.4) 174 (56.7)
25–29 253 (36.8) 120 (31.6) 133 (43.3)
Gender identity 0.0 (0.98)
Man 669 (97.4) 370 (97.4) 299 (97.4)
Other 18 (2.6) 10 (2.6) 8 (2.6)
Sexual orientation 2.6 (0.27)
Gay 551 (80.2) 313 (82.4) 238 (77.5)
Bisexual 119 (17.3) 58 (15.3) 61 (19.9)
Other 17 (2.5) 9 (2.4) 8 (2.6)
Sexual behavior 3.3 (0.07)
Men only 560 (81.5) 319 (83.9) 241 (78.5)
Men and women 127 (18.5) 61 (16.1) 66 (21.5)
Employment 10.6 (0.01)
Employed full time 273 (39.7) 140 (36.8) 133 (43.3)
Employed part time 157 (22.8) 81 (21.3) 76 (24.8)
Full time student 168 (24.5) 111 (29.2) 57 (18.6)
Other 89 (13.0) 48 (12.6) 41 (13.4)
Educationa 9.8 (0.007)
Less than high school 44 (6.4) 17 (4.5) 27 (8.8)
Completed high school 143 (20.8) 92 (24.2) 51 (16.6)
Some college and above 496 (72.2) 270 (71.1) 226 (73.6)
Incomea 9.1 (0.01)
<$9999 176 (25.6) 112 (29.5) 64 (20.8)
$10,000–$29,999 254 (37.0) 134 (35.3) 120 (39.1)
>$30,000 196 (28.5) 95 (25.0) 101 (32.9)
Current insurance 509 (74.1) 287 (75.5) 222 (72.3) 0.9 (0.34)
Homeless in last year 47 (6.8) 23 (6.1) 24 (7.8) 0.8 (0.36)
US citizen 616 (89.7) 342 (90.0) 274 (89.3) 0.4 (0.53)
aFive participants declined to answer education question, 61 participants did not provide income.
SD, standard deviation.
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Table 2. Sexual Risk Behavior and Substance Abuse Risk Among Younger Men Who Have
Sex with Men in California by Willingness (n = 687)
Variable Total, n (%)
Willing,
n (%)
Unwilling
or uninterested,
n (%) v2 (p value)
How would you rate your risk of getting HIV 5.4 (0.07)
Low 297 (43.2) 156 (41.1) 141 (45.9)
Moderate 288 (41.9) 156 (41.1) 132 (43.0)
High 71 (10.3) 48 (12.6) 23 (7.5)
Last HIV test 11.9 (0.008)
<6 months ago 356 (51.8) 203 (53.4) 153 (49.8)
6–12 months ago 142 (20.7) 64 (16.8) 78 (25.4)
>12 months ago 95 (13.8) 50 (13.2) 45 (14.7)
I’ve never been tested 94 (13.7) 63 (16.6) 31 (10.1)
How concerned are you about becoming
infected with HIV
30.0 (<0.001)
Not concerned 181 (26.3) 69 (18.2) 112 (36.5)
Somewhat concerned 217 (31.6) 129 (33.9) 88 (28.7)
Very concerned 289 (42.1) 182 (47.9) 107 (34.9)
Number of men had sex with in the last 6 months 8.1 (0.09)
0 32 (4.7) 12 (3.2) 20 (6.5)
1 106 (15.4) 53 (13.9) 53 (17.3)
2–5 295 (42.9) 163 (42.9) 132 (43.0)
6 or more 254 (37.0) 152 (40.0) 102 (33.3)
Average number of male sexual partners
in the past 6 months (SD)
7 (20.7) 9 (27.3) 5 (5.8)
Median number of male sexual partners
in the past 6 months (IQR)
4 (2–8) 4 (2–8) 4 (2–7)
Had receptive condomless anal sex
with a man in last 6 months
360 (52.4) 224 (58.9) 136 (44.3) 14.6 (<0.001)
Had an HIV-positive male partner
in the last 6 months
73 (10.6) 44 (11.6) 29 (9.4) 0.8 (0.37)
Had insertive condomless anal sex with
an HIV-positive man in last 6 months
151 (22.0) 88 (23.2) 63 (20.5) 0.7 (0.41)
Main HIV-positive partner currently 23 (3.3) 11 (2.9) 12 (3.9) 0.5 (0.46)
Condom use all the time for anal sex
in the last 6 months
236 (34.4) 126 (33.2) 110 (35.8) 0.5 (0.46)
Substances in the last 6 months
Alcohol 529 (77.0) 298 (78.4) 231 (75.2) 1.0 (0.33)
Marijuana/pot 299 (43.5) 166 (43.7) 133 (43.3) 0.0 (0.92)
Poppers 148 (21.5) 79 (20.8) 69 (22.5) 0.3 (0.59)
Other illicit drugs 116 (16.9) 75 (19.7) 41 (13.4) 4.9 (0.03)
Methamphetamine/crystal 31 (4.5) 20 (5.3) 11 (3.6)
Heroine 2 (0.3) 2 (0.5) 0 (0.0)
Cocaine/crack 46 (6.7) 32 (8.4) 14 (4.6)
Ecstasy/MDMA/Molly 80 (11.6) 53 (13.9) 27 (8.8)
Ketamine/special k 8 (1.2) 5 (1.3) 3 (1.0)
GHB 16 (2.3) 10 (2.6) 6 (2.0)
Ever exchanged sex for money, drugs,
or place to stay
79 (11.5) 47 (12.4) 32 (10.4) 0.6 (0.43)
Any STD diagnosis in the past year 134 (19.5) 72 (18.9) 62 (20.2) 0.2 (0.68)
Gonorrhea 69 (10.0) 34 (8.9) 35 (11.4)
Chlamydia 64 (9.3) 31 (8.2) 33 (10.7)
Syphilis 27 (3.9) 16 (4.2) 11 (3.6)
Other 18 (2.6) 10 (2.6) 8 (2.6)
Last STD test 3.3 (0.35)
<6 months ago 331 (48.2) 183 (48.2) 148 (48.2)
6–12 months ago 154 (22.4) 77 (20.3) 77 (25.1)
>12 months ago 110 (16.0) 64 (16.8) 46 (15.0)
I’ve never been tested 92 (13.4) 56 (14.7) 36 (11.7)
CDC’s HIV risk index score 10.4 (0.001)
Low (<10) 237 (31.1) 109 (28.7) 124 (40.4)
High (‡10) 524 (68.9) 271 (71.3) 183 (59.6)
IQR, interquartile range; SD, standard deviation; STD, sexually transmitted disease.
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ability to adhere to PrEP were associated with decreased will-
ingness (OR: 0.65; CI: 0.49–0.88; p< 0.005). Higher scores in
perceived benefits of PrEP were associated with higher odds of
willingness (OR: 2.59; CI: 1.78–3.78). See Table 5 for full
multivariabe regression results.
Discussion
This study examined willingness to take PrEP, and its as-
sociated facilitators and barriers, by simultaneously exam-
ining a full range of factors, including the demographic
characteristics, sexual risk, and substance use behavior, and
attitudes toward PrEP for a diverse group of California
YMSM who use GSN apps. Previous investigations exam-
ined facilitators and barriers to PrEP uptake qualitatively;
others used single-item attitudinal measures that may not
fully elucidate key domains related to PrEP use.23,33,44,46,64
Attitudinal factors including drug effects, perceived benefits,
medical mistrust, and adherence were all significantly asso-
ciated with willingness to take PrEP after adjusting for other
Table 3. Principal Component Analysis on Attitudes Toward Pre-Exposure Prophylaxis
Factor Item Loading
1. Access/
affordability
I wouldn’t be able to take PrEP because I don’t have a doctor or healthcare provider 0.85
I wouldn’t be able to take PrEP because I don’t have health insurance 0.83
I don’t know how to enroll in health insurance so I can start taking PrEP 0.79
I wouldn’t be able to afford PrEP 0.62
I don’t know how to find a doctor who can give me a PrEP prescription 0.62
I don’t know where to go to get a PrEP prescription 0.54
2. Stigma I would be concerned about family members finding out if I started taking PrEP 0.67
I would be concerned about friends finding out if I started taking PrEP 0.66
I would be uncomfortable asking a doctor for PrEP prescription 0.70
I would be uncomfortable talking to a doctor about my sexual behavior 0.70
I would be concerned about sex partners finding out if I started taking PrEP 0.63
3. Drug effects Not knowing if there are long-term side effects of taking PrEP
makes me very uncomfortable
0.77
I am concerned about side effects or feeling sick from taking PrEP 0.77
I am concerned that PrEP is only partially effective 0.54
I would be very uncomfortable taking HIV medicines when I don’t have HIV 0.49
I would take PrEP if there weren’t any side effectsa 0.47
4. Perceived benefits Taking PrEP would be a good way to protect myself from getting HIV 0.76
PrEP would help me worry less about getting HIV 0.73
PrEP use should be encouraged to prevent the spread of HIV 0.72
I would use condoms less if I started taking PrEP
5. Risk compensation I am concerned that I would take more sexual risks if I started taking PrEP 0.78
I think people who take PrEP will take more sexual risks 0.64
6. Lack of perceived
need
I don’t need PrEP because I always use condoms 0.75
I don’t need PrEP because I’m not at risk for getting HIV 0.68
7. Mistrust I don’t trust doctors or healthcare providers 0.57
I don’t trust drug companiesb 0.58
8. Adherence It would be difficult for me to remember to take PrEP every day 0.47
It would be difficult for me to see my doctor every 2–3 months
for follow-up if I started taking PrEP
0.61
aCross-loaded with Factor 8.
bCross-loaded with Factor 3.
PrEP, pre-exposure prophylaxis.
Table 4. Attitudes Toward Pre-Exposure Prophylaxis Among Younger Men Who Have
Sex with Men in California by Willingness (n= 687)
Variable
Total Willing Unwilling or uninterested Mann-Whitney
U (p value)Mean (SD) Mean (SD) Mean (SD)
Access/affordability 2.4 (0.7) 2.4 (0.8) 2.3 (0.7) 101019.5 (0.08)
Stigma 2.1 (0.7) 2.0 (0.7) 2.3 (0.7) 116870.5 (<0.001)
Drug effects 2.6 (0.7) 2.4 (0.7) 2.8 (0.6) 125448.5 (<0.001)
Perceived benefits 3.3 (0.6) 3.5 (0.6) 3.0 (0.6) 82656.5 (<0.001)
Risk compensation 2.4 (0.7) 2.3 (0.7) 2.5 (0.7) 117502.5 (<0.001)
Lack of perceived need 2.0 (0.7) 1.8 (0.7) 2.1 (0.7) 121198 (<0.001)
Mistrust 2.0 (0.8) 1.8 (0.8) 2.2 (0.8) 121198 (<0.001)
Adherence 2.0 (0.7) 1.9 (0.7) 2.3 (0.7) 123892 (<0.001)
SD, standard deviation.
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covariates. Future efforts to educate YMSM about PrEP, and
engage YMSM in PrEP screening, must pay careful attention
to these factors to improve uptake within YMSM commu-
nities.
In addition to attitudes about PrEP, Hispanic/Latino eth-
nicity and concern for contracting HIV were both signifi-
cantly positively associated with willingness to take PrEP.
California leads the United States in its total number of La-
tino residents65 and Latinos make up the largest number of
new HIV/AIDS cases in the state.66 Latino YMSM may be
particularly vulnerable to HIV due to lack of health insur-
ance, language barriers, and other cultural factors that impede
their ability to negotiate safer sex.67 Our data suggest high
PrEP willingness among Latino YMSM, indicating the need
for culturally and linguistically tailored programs to en-
courage PrEP uptake in this population.
The relationship between concern for contracting HIV and
willingness has been well documented.32,35,38,68 These data
are consistent with the Health Belief Model, which posits that
perceived susceptibility is a key antecedent to behavior
change,69 and may indicate that messaging about PrEP is
reaching some of its target audience, as those who perceive
themselves at greater risk display greater willingness to take
PrEP. Opportunities for YMSM to reflect on engagement in
risk behaviors and encouragement to assess HIV risk may be
one strategy for increasing PrEP willingness.70 Recent efforts
to characterize motivation for PrEP use consider willingness
as part of the PrEP Contemplation Stage, which is an im-
portant precursor to PrEP uptake.28
Adherence to PrEP is a common concern amongMSM and
YMSM.26,34,71 Efficacy studies demonstrate that even with
suboptimal adherence, PrEP can be up to 96% effective.16
These data must be disseminated widely to YMSM and the
medical providers who serve them to allay fears that missing
doses forecloses a PrEP prescription. Instead, clear and ac-
cessible information about PrEP adherence, strategies for
remembering to take the medication, and guidance about
what to do if a dose is missed should be highlighted. In our
earlier work on PrEP uptake and adherence with YMSM, we
found that, although 90% of current PrEP users reported
taking their medication 6–7 times/week, difficulty in re-
membering to take it was one of the top reasons they dis-
continued it.72 Other research on PrEP adherence for YMSM
shows that nearly two-thirds are adherent.73 These data
suggest the need for further research on barriers and facili-
tators to PrEP adherence among YMSM to ensure optimal
outcomes for users. Future developments in PrEP, such as
long-term injectable formats and on-demand PrEP, may be
promising solutions to address adherence concerns among
YMSM.52,74–76
Greater medical mistrust was associated with less will-
ingness to take PrEP, highlighting the need to address wari-
ness with the health system amongYMSM. Previous research
documents medical mistrust among both racial/ethnic mi-
nority and sexual minority communities.77,78 For example, a
study of blackMSM by Eaton et al.39 showed that nearly one-
fifth do not trust doctors and healthcare workers. Another
study by Mutchler et al.79 noted high levels of misconcep-
tions and mistrust about PrEP among black YMSM and their
close friends, including skepticism about the efficacy of PrEP
and fears that PrEP might cause people to develop HIV.
While we did not see an interaction effect by race/ethnicity in
our data, the literature on medical mistrust among black
communities is robust.77,80–83 Community-based agencies
focused on LGB/T health have disseminated guidelines for
providers to increase cultural competence in working with
sexual minority men.84 More work should be done on in-
creasing PrEP knowledge and attitudes in communities of
color.46 In addition, researchers have noted the importance of
attitudes among care providers when discussing PrEP with
Table 5. Multivariate Logistic Regression
Predicting Willingness to Take Pre-Exposure
Prophylaxis Among Younger Men Who Have
Sex with Men in California (n= 687)
Variable Odds ratio 95% CI p
Race/ethnicity
White Ref.
Black/African American 1.27 0.73–2.21 0.397
Hispanic/Latino 1.73 1.01–2.98 0.046
Other/mixed 1.03 0.57–1.85 0.922
Age
18–24 Ref.
25–29 0.70 0.47–1.06 0.090
Employment
Employed full time Ref.
Employed part time 0.89 0.52–1.51 0.655
Full time student 1.51 0.88–2.60 0.134
Other 0.83 0.44–1.57 0.561
Education
Less than high school Ref.
Completed part time 1.35 0.55–3.30 0.510
Some college and above 1.15 0.51–2.64 0.734
Income
<$9999 Ref.
$10,000–$29,999 0.88 0.54–1.44 0.613
>$30,000 1.08 0.61–1.93 0.786
Last HIV test
<6 months ago Ref.
6–12 months ago 0.72 0.44–1.18 0.196
>12 months ago 1.10 0.63–1.92 0.737
I’ve never been tested 1.31 0.70–2.43 0.398
Concern for getting HIV
Low Ref.
Medium 1.87 1.14–3.07 0.014
High 1.84 1.13–3.01 0.015
Had receptive condomless anal sex with a man in last
6 months
No Ref.
Yes 1.32 0.91–1.93 0.145
Other illicit drug usea
No Ref.
Yes 1.50 0.89–2.52 0.125
Stigma 1.07 0.78–1.47 0.678
Drug effects 0.46 0.33–0.65 <0.001
Perceived benefits 2.59 1.78–3.78 <0.001
Risk compensation 0.83 0.62–1.11 0.204
Lack of perceived need 0.85 0.62–1.15 0.291
Medical mistrust 0.71 0.53–0.96 0.026
Adherence 0.65 0.49–0.88 0.005
aIncludes Methamphetamine/crystal, heroine, cocaine/crack, ec-
stasy/MDMA/Molly, ketamine/special K, GHB.
CI, confidence interval.
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YMSM. In a recent mixed methods study of clinicians in-
volved in the NIH-funded Adolescent Medicine Trials Net-
work for HIV/AIDS Interventions (ATN), Mullins et al.
found that most thought the CDC guidelines were compatible
with their practice; however, there was variability in what
they considered to be appropriate characteristics for suitable
candidates.85 Other studies highlight that providers’ will-
ingness to prescribe PrEP is associated with PrEP knowl-
edge86 and experience in treating HIV-positive people,87,88
suggesting that resources be devoted to PrEP training for
clinicians in general, since YMSM are more likely to be seen
by general practitioners than HIV specialists,89 and PrEP
navigation for YMSM patients.79
Previous research indicates YMSM are concerned about
PrEP’s long-term side effects.23,68 Fatigue, nausea, and
headache have been documented and YMSM should be given
strategies to alleviate these symptoms and encouraged to
continue the medication, as side effects often resolve with a
few weeks.90 Literature on ‘‘seasons of risk’’ highlights
particular times when individuals may be at an elevated risk
for acquiring STIs, including HIV.74 Providers should be
attuned to these times that may elevate HIV risk for YMSM
and emphasize that PrEP does not necessarily require long-
term use. Rather, YMSM, in partnership with their providers,
can evaluate their use of PrEP over time during routine
medical visits to ensure that decisions regarding PrEP uptake
and discontinuation are based on accurate risk assessment. As
new evidence regarding long-term side effects of PrEP be-
comes available, providers should share it with their patients.
In this study, perceived benefits of PrEP, including the
belief that PrEP offered effective protection against HIV and
taking PrEP would decrease worry about infection, were
associated with greater willingness. Popular discourse around
PrEP has sometimes promoted negative images of those who
use it. For instance, PrEP users have been called ‘‘irrespon-
sible’’ and ‘‘promiscuous.’’40 This messaging can be dam-
aging to community perceptions about the benefits of
PrEP.41,91 In response, more can be done to increase positive
associations with PrEP. Reframing PrEP users as knowl-
edgeable, responsible men who take an active role in main-
taining their health may increase positive associations with
PrEP. Providing empirically based, accessible information
about PrEP’s efficacy can also increase knowledge of its
benefits, which are associated with increased willingness to
take PrEP.
Limitations
This research should be interpreted in light of several
limitations, including convenience sampling and the use of
willingness as a primary outcomemeasure. Previous research
has highlighted differences in willingness to use PrEP, in-
tentions to use PrEP, and actual PrEP uptake.47,92 Future
work should seek to measure all three of these outcomes, in
addition to other important stages of the PrEP cascade (e.g.,
adherence and discontinuation).28 In addition, participants
for this study were a self-selected group, whichmay represent
a bias toward those who are more interested in PrEP, and,
being from California, may not represent YMSM across the
country. Data were self-reported, which may mean over- or
under-reporting of willingness to take PrEP. Finally, while
we derived a comprehensive list of attitudes based on the
extant literature, we may have missed important issues for
YMSM that influence willingness to take PrEP.
Despite the limitations enumerated above, this study
contributes to a growing body of literature on factors that
influence YMSM’s willingness to take PrEP. Prioritizing
concerns related to adherence, medical mistrust, and medi-
cation side effects in campaigns that promote PrEP may in-
crease interest in and demand for PrEP among YMSM. Once
enrolled, providers should speak openly and honestly with
YMSM on PrEP about what to do if side effects occur and
how to handle missed doses. Providers should also highlight
PrEP’s limitations, such as its failure to protect against other
STIs, as well as its benefits, such as its potential to reduce
anxiety around HIV infection. Any step YMSM take to ad-
dress their sexual health and wellbeing should be seen as an
opportunity to educate them about PrEP. For example, as part
of AB2640, California now requires that information about
PrEP be provided as part of HIV post-test counseling.93 GSN
apps may facilitate this process given their popularity among
YMSM. Future research should focus on how to foster these
opportunities and measure their effectiveness at increasing
PrEP willingness and uptake among YMSM.
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